Roivios Reports Promising Results from First-in-Human Trial of JuxtaFlow® Renal Assist Device

Roivios, a pioneering clinical-stage medical device company dedicated to revolutionizing kidney health, today announced promising results from the first human trial of its JuxtaFlow Renal Assist ...
Renal & Urology News

Combination Therapy of SGLT2 Inhibitors, GLP-1RAs Yields Cardiorenal Benefits

GLP-1RA and SGLT2 inhibitor combination therapy was associated with better cardiorenal outcomes than monotherapy among patients with type 2 diabetes. The cardiorenal benefits of sodium-glucose ...
Healio

Obesity medications can tackle metabolic cardiorenal disease

Please provide your email address to receive an email when new articles are posted on . In previous First Word columns, I discussed the effects of SGLT2 inhibitors on the kidney to prevent progression ...
Medscape

How Do You Holistically Manage Triglycerides and HDL for Cardiorenal Metabolic Syndrome?

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Pam Taub, MD, FACC ...
Morningstar

SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy

DENVER, May 28, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing ...
Medscape

Cardiorenal Syndrome in Acute Decompensated Heart Failure

Expert Rev Cardiovasc Ther. 2012;10(2):177-189. Therefore, patients with HF may especially benefit from prompt correction of their hyponatremia, [84] so that other necessary therapies are not ...